These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3053574)

  • 41. Determination of MICs for staphylococci using the API ATB quinolone and API ATB macrolide systems.
    Rohner P; Peyret M; Auckenthaler R
    Pathol Biol (Paris); 1993 Apr; 41(4):323-8. PubMed ID: 8233630
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Postantibiotic effect of ciprofloxacin compared with that of five other quinolones.
    Minguez F; Ramos C; Barrientos S; Loscos A; Prieto J
    Chemotherapy; 1991; 37(6):420-5. PubMed ID: 1760941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.
    Wagenlehner FM; Kinzig-Schippers M; Tischmeyer U; Wagenlehner C; Sörgel F; Naber KG
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3947-9. PubMed ID: 16982785
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
    Zhao X; Quinn B; Kerns R; Drlica K
    J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Antibacterial activity of ciprofloxacin against fresh clinical isolates from superficial suppurative foci].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Sato K
    Jpn J Antibiot; 1991 Feb; 44(2):117-29. PubMed ID: 2041153
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigation of Smith's quinolone killing mechanisms during the PAE of ciprofloxacin on Escherichia coli.
    Wickens HJ; Pinney RJ
    Int J Pharm; 2001 Oct; 227(1-2):149-56. PubMed ID: 11564549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae.
    Lemmen SW; Häfner H; Klik S; Lütticken R; Zolldann D
    Chemotherapy; 2003 May; 49(1-2):33-5. PubMed ID: 12714807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
    D'Arienzo PA; Wagner RS; Jamison T; Bell B; Dajcs JJ; Stroman DW
    Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Comparative study on growth kinetics of organisms causing purulent infections in the presence of ofloxacin and ciprofloxacin].
    Skala LZ
    Antibiot Khimioter; 1991 Nov; 36(11):21-4. PubMed ID: 1793289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro investigation of the intraphagocytic bioactivities of ciprofloxacin and the new fluoroquinolone agents, clinafloxacin (CI-960) and PD 131628.
    Anderson R; Jooné GK
    Chemotherapy; 1993; 39(6):424-31. PubMed ID: 8222871
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibacterial activity of a 1,8-naphthyridine quinolone, PD 131628.
    Lewin CS
    J Med Microbiol; 1992 May; 36(5):353-7. PubMed ID: 1316970
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intracellular bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis H37Rv multiplying in the J-774 macrophage cell line.
    Rastogi N; Blom-Potar MC
    Zentralbl Bakteriol; 1990 Jun; 273(2):195-9. PubMed ID: 2119180
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lytic effect of two fluoroquinolones, ofloxacin and pefloxacin, on Escherichia coli W7 and its consequences on peptidoglycan composition.
    Vincent S; Glauner B; Gutmann L
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1381-5. PubMed ID: 1929297
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gut decontamination by oral ofloxacin and ciprofloxacin in healthy volunteers.
    van Saene HK; Lemmens SE; van Saene JJ
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():127-34. PubMed ID: 3182454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth.
    Zeiler HJ
    Antimicrob Agents Chemother; 1985 Oct; 28(4):524-7. PubMed ID: 2934022
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of ofloxacin and ciprofloxacin on pentylenetetrazol-induced convulsions in mice.
    Enginar N; Eroğlu L
    Pharmacol Biochem Behav; 1991 Jul; 39(3):587-9. PubMed ID: 1784588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.